American Society of Hematology

Oncology & Cancer

JAK inhibitors associated with aggressive lymphoma

Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.

Medications

Experts: High drug price trend has 'infected' generics

An article published online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that pharmaceutical companies use several strategies to keep affordable generic drugs from the market, illustrating ...

page 7 from 15